Jeff Williamson has joined the RNA Advisors growing healthcare practice as Director. Mr. Williamson will focus on providing a greater breadth and depth of strategic advisory services to our healthcare, medical device, and life sciences clients.
Mr. Williamson brings over 15 years of strategy consulting experience in healthcare and life sciences, with particular expertise in provider & payer strategy, population health management, biopharma commercial forecasting, and epidemiology. He has led project teams to assist healthcare companies in addressing a number of key strategic issues, including market sizing & assessment, operational improvement, new product launches, competitive analysis, and due diligence support for both buy-side and sell-side clients. He has deep experience in forecasting, analytics, and strategic planning across a broad range of therapeutic areas.
Prior to joining RNA, Mr. Williamson was an Engagement Manager in L.E.K. Consulting’s Healthcare practice, and served as the Vice President of Market Access for an oncology startup that provides genetic sequencing services and therapy recommendations for patients with cancer. Mr. Williamson earned MBA and MPH degrees from the University of California, Berkeley.
Sam Renwick, founding partner of RNA, said, “Increasingly, our clients are requesting help to devise strategies to capitalize on market opportunities. Adding Jeff to our strategic advisory practice will allow us to increase the depth and breadth of services we can offer to client company leadership teams.”
Jeff Williamson commented, “RNA Advisors has carried over the same high standard it has set in financial & valuation services to strategic advisory projects that help clients transform market possibilities into commercial realities. I look forward to further developing RNA’s strategic consulting practice to help clients realize the full potential of their opportunities.”
About RNA Advisors
RNA Advisors is a leading financial advisory and valuation consulting firm focused exclusively in the life sciences and healthcare sectors. Since the firm’s founding in 2015, RNA Advisors has provided over 300 clients across life sciences and healthcare verticals with strategic decision analysis, valuation, and transactional support for 1700+ transactions worth over $282 billion in asset and transaction value. RNA assists life sciences and healthcare technology companies and investors by providing research, analysis and consulting support for highly strategic transactions, acquisitions, and commercial partnerships. RNA Advisors’ clients include private venture-backed and public companies in biotech, biopharmaceuticals, digital health, medical devices, healthcare services and technology, as well as royalty stream investors, potential joint venture partners, M&A transaction counterparties, financiers and licensors/licensees. RNA’s deeply experienced team includes 20+ consultants and analysts delivering high-level to deep-dive market assessments, market research, comparative valuation analyses, and financial modeling and forecasts which support decision making around corporate growth strategies. RNA Advisors also delivers end-to-end transaction support in the form of fairness opinions, intellectual property valuations, asset and enterprise valuations, drug royalty forecasts, derivative security valuations, pro forma capitalization table modeling, and gift/estate tax valuations for investors. Learn more about RNA Advisor client success stories at rnaadvisors.com.
RNA Capital Advisors